RAS inhibitors, beta blockers after discharge improve outcomes in MI with mid range EF

Published On 2022-03-25 02:30 GMT   |   Update On 2022-03-25 04:24 GMT
Advertisement

Beta-blocker therapy at discharge in patients with mildly reduced left ventricular ejection fraction after acute myocardial infarction (MI) was associated with lower 2-year rates of major adverse cardiac events (MACE). The Renin-angiotensin-system (RAS) inhibitor therapy at discharge after acute MI with heart failure with mildly reduced EF was associated with lower rates of rehospitalization due to heart failure. Furthermore, the Patients with mildly reduced LVEF after acute MI had better 2-year clinical outcomes if they were on beta blockers or RAS inhibitors at discharge.The findings suggest that beta blockers and RAS inhibitors can be considered in patients with mildly reduced LVEF after an acute MI in the era of early coronary reperfusion therapy and contemporary optimal medical therapies. 

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News